The objective of study is to develop a new stability-indicating HPLC method for quantifying ixabepilone degradation products and known process impurities (EPO-2 and Epothilone B) in bulk and injectable dose forms. A gradient stability-indicating RP-HPLC approach was developed to determine the known impurities of ixabepilone in ixabepilone API and ixabepilone for injection. Ixabepilone was subjected to base, acid, oxidation, photolytic and thermal degradations. The gradient approach was used to optimize the mobile phase-A [pH 4.8 acetate buffer (10 mM) and acetonitrile 90:10 v/v] and mobile phase-B [pH 4.8 acetate buffer (10 mM) and acetonitrile 20:80 v/v] of a USP L1 column. A wavelength of 250 nm was chosen based on known impurities and degradation products response, with a 1.0 mL/min flow rate. In compliance with ICH criteria Q2(R1), the developed technique was validated. The stability-indicating-related impurities technique was proven to be appropriate for estimating degrading impurities and known impurities in ixabepilone API and ixabepilone injection.
Colloidosomes, pioneering microcapsules composed of coagulated colloidal particles assembled at the interface of emulsion droplets, have garnered significant attention due to their remarkable properties and potential applications in targeted and controlled drug delivery. Their unique core-shell architecture offers unparalleled advantages, including tunable permeability, mechanical strength and encapsulation capabilities for a wide range of therapeutic agents. These versatile carriers have demonstrated remarkable potential in delivering small molecules, biomacromolecules, genetic materials and even living cells, addressing challenges associated with conventional drug delivery systems. Colloidosomes can be fabricated through various techniques, encompassing emulsion-based, nature-of-colloids-based and emerging methods such as microfluidics and 3D printing. Comprehensive characterization, employing techniques like electron microscopy, spectroscopy and rheology, is crucial for understanding their structural, physical and functional properties. Remarkable advancements have been achieved in developing stimuli-responsive, targeted and multi-functional colloidosomes, enabling precise spatiotemporal control, selective accumulation and integrated functionalities for theranostic applications. Despite their immense potential, challenges remain in scaling up production, ensuring long-term stability, navigating regulatory landscapes and facilitating clinical translation. Addressing these obstacles through collaborative efforts, advanced characterization and the integration of emerging technologies is paramount for unlocking the full potential of colloidosomes in revolutionizing drug delivery strategies and realizing personalized medicine.
Background: An eco-friendly analytical technique was developed with the intention of preserving the environment by using green chemistry principles. Pemetrexed is a folate analogue indicated for the treatment of advanced lung cancer. Objective: Development of a green stability-indicating HPLC method for the quantification of pemetrexed ditromethamine (PDT) impurities in Active Pharmaceutical Ingredient (API) and parenteral dosage form. Methods: Chromatographic separation was achieved using a Zorbax SB C18 column (150 mm × 4.6 mm i.d., 3.5 µ particle size) with perchlorate buffer (pH 3.0 ± 0.1, 50 mM) as mobile phase A and acetonitrile–perchlorate (90 + 10, v/v) buffer as mobile phase B at a flow rate of 0.8 mL/min with a column temperature of 40°C ± 0.5°C. All analytes were well resolved by gradient elution with a total run time of 75 min. The UV detection wavelength was 230 nm. Results: The RP-HPLC method is capable of resolving all the degradation and process impurities for PDT API and parenteral dosage form. The related compounds method was validated in accordance with International conference on harmonization (ICH) Q2(R1) and United states of Pharmacopoeia (USP) guidelines, and found to be accurate, specific, precise, linear, robust and stability-indicating. The precision and intermediate results were <5% CV for all the impurities. The accuracy for all the impurities was found to be between 90 and 110%. The linearity of regression co-efficient values for all the impurities were found to be more than 0.999. Conclusion: The proposed related compounds method is found suitable for the determination of process and degradation impurities of commercial formulations, stability samples in QC analysis for PDT API, and drug product. Highlights: The developed liquid chromatographic method greenness and eco-friendliness were assessed using the green analytical procedure index (GAPI) and the analytical greenness (AGREE) tool, and found to be green. A PDT detoxification procedure was also developed to reduce environmental pollution.